在心血管药物中毒中体外膜氧化. 一项德国范围内的回顾性研究
Benjamin Friedrichson1, Thomas Jasny2, Oliver Old2
1Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. ben@dsgfrankfurt.de.
Scientific reports
|September 18, 2024
概括
静脉外体膜氧化 (V-A ECMO) 为因药物中毒引起的严重心血管衰竭提供了可行的治疗方法,在一项德国研究中实现了63.6%的生存率. 结构化的V-A ECMO实施可以改善这些关键患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 毒理学 毒理学 毒理学
- 关键护理医学 关键护理医学
背景情况:
- 由心脏毒药物引起的药物中毒导致显著的死亡率.
- 在这些情况下,心肌功能障碍往往对标准治疗不耐药.
- 静脉外体膜氧化 (V-A ECMO) 提供暂时的循环支持.
研究的目的:
- 评估V-A ECMO在治疗因药物中毒引起的心血管崩方面的有效性.
- 分析这个特定患者队列中的患者特征,并发症和结果.
主要方法:
- 德国医院住院患者数据的回顾性分析 (2007-2022年).
- 纳入标准:为心血管药物中毒而使用V-A ECMO治疗的患者.
- 描述性统计和幸存者与非幸存者之间的比较分析.
主要成果:
- 49名患者因药物中毒而接受V-A ECMO治疗,总生存率为63.6%.
- 常被摄入的药物包括通道阻断剂和β阻断剂.
- 与幸存者相比,非幸存者的住院心肺复苏率较高 (50%对12.9%).
结论:
- V-A ECMO是一种可行的,可能拯救生命的干预措施,用于因药物中毒引起的心血管衰竭.
- 早期V-A ECMO植入 (24小时内) 是常见的,但没有显著改变存活率.
- 对药物中毒的V-A ECMO采用标准化的方法可以提高生存率.
相关概念视频
Prevention of Further Absorption of Poison
795
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
795
Acute Respiratory Failure-V
124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
Heart Failure Drugs: Inotropic Agents
539
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539
Acute Respiratory Failure-III
162
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
162


